HMC通过抑制ATP7A的去泛素化和稳定来改善心肌缺血再灌注损伤。

IF 7.7 2区 医学 Q1 PHARMACOLOGY & PHARMACY
Jia-Bao Su, You-Yi Zhuang, Ming-Heng Liu, Guo Chen, Min Wei, Bing-Xin Chen, Le Yang, Yun-Feng Ji, Chuan Zhu, Xue-Xue Zhu, Ji-Ru Zhang, Hai-Jian Sun
{"title":"HMC通过抑制ATP7A的去泛素化和稳定来改善心肌缺血再灌注损伤。","authors":"Jia-Bao Su, You-Yi Zhuang, Ming-Heng Liu, Guo Chen, Min Wei, Bing-Xin Chen, Le Yang, Yun-Feng Ji, Chuan Zhu, Xue-Xue Zhu, Ji-Ru Zhang, Hai-Jian Sun","doi":"10.1111/bph.70171","DOIUrl":null,"url":null,"abstract":"<p><strong>Background and purpose: </strong>Myocardial ischaemia-reperfusion injury (MI/RI) is a major contributor to poor prognosis following revascularization in myocardial infarction patients, yet targeted therapies remain elusive. While hesperidin methyl chalcone (HMC) demonstrates antioxidant and vasoprotective properties, its role in modulating regulated cell death pathways during MI/RI is undefined. This study investigates the cardioprotective effects of HMC against MI/RI and its underlying mechanisms.</p><p><strong>Experimental approach: </strong>Hypoxia/reoxygenation (H/R) models in H9c2 cardiomyocytes and a model of MI/RI in mice were employed. The effects of HMC on cardiac performance, copper flux analysis, ubiquitination assays and molecular docking, mitochondrial integrity and cell death modalities in response to MI/RI were examined.</p><p><strong>Key results: </strong>HMC pretreatment exhibited significant cardioprotection, reducing infarct size and improving cardiac function in MI/RI mice. Mechanistically, HMC specifically attenuated cuproptosis, as evidenced by decreased copper overload and downregulation of cuproptosis effectors, mimicking the action of the copper chelator ammonium tetrathiomolybdate (ATTM). Crucially, the cuproptosis inducer elesclomol-Cu (Es-Cu) abolished the cardioprotective effects of HMC. Furthermore, HMC interacted with the E3 ubiquitin ligase MARCHF7, and disrupted the complex of MARCHF7/ATP7A, thereby reducing ubiquitination and proteasomal degradation of the copper exporter ATP7A. The stabilization of ATP7A enhanced copper efflux, alleviating cuproptosis, oxidative stress, inflammation and mitochondrial damage induced by MI/RI.</p><p><strong>Conclusions and implications: </strong>Our work unveils a ubiquitin-regulated copper homeostasis axis in MI/RI. By targeting MARCHF7-ATP7A interaction, HMC sustains copper export machinery to combat cuproptosis-driven injury. These findings position HMC as a novel therapeutic candidate for MI/RI through regulating ubiquitination-dependent regulation of copper homeostasis.</p>","PeriodicalId":9262,"journal":{"name":"British Journal of Pharmacology","volume":" ","pages":""},"PeriodicalIF":7.7000,"publicationDate":"2025-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"HMC ameliorates myocardial ischaemia-reperfusion injury through suppressing cuproptosis via the de-ubiquitination and stabilization of ATP7A.\",\"authors\":\"Jia-Bao Su, You-Yi Zhuang, Ming-Heng Liu, Guo Chen, Min Wei, Bing-Xin Chen, Le Yang, Yun-Feng Ji, Chuan Zhu, Xue-Xue Zhu, Ji-Ru Zhang, Hai-Jian Sun\",\"doi\":\"10.1111/bph.70171\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background and purpose: </strong>Myocardial ischaemia-reperfusion injury (MI/RI) is a major contributor to poor prognosis following revascularization in myocardial infarction patients, yet targeted therapies remain elusive. While hesperidin methyl chalcone (HMC) demonstrates antioxidant and vasoprotective properties, its role in modulating regulated cell death pathways during MI/RI is undefined. This study investigates the cardioprotective effects of HMC against MI/RI and its underlying mechanisms.</p><p><strong>Experimental approach: </strong>Hypoxia/reoxygenation (H/R) models in H9c2 cardiomyocytes and a model of MI/RI in mice were employed. The effects of HMC on cardiac performance, copper flux analysis, ubiquitination assays and molecular docking, mitochondrial integrity and cell death modalities in response to MI/RI were examined.</p><p><strong>Key results: </strong>HMC pretreatment exhibited significant cardioprotection, reducing infarct size and improving cardiac function in MI/RI mice. Mechanistically, HMC specifically attenuated cuproptosis, as evidenced by decreased copper overload and downregulation of cuproptosis effectors, mimicking the action of the copper chelator ammonium tetrathiomolybdate (ATTM). Crucially, the cuproptosis inducer elesclomol-Cu (Es-Cu) abolished the cardioprotective effects of HMC. Furthermore, HMC interacted with the E3 ubiquitin ligase MARCHF7, and disrupted the complex of MARCHF7/ATP7A, thereby reducing ubiquitination and proteasomal degradation of the copper exporter ATP7A. The stabilization of ATP7A enhanced copper efflux, alleviating cuproptosis, oxidative stress, inflammation and mitochondrial damage induced by MI/RI.</p><p><strong>Conclusions and implications: </strong>Our work unveils a ubiquitin-regulated copper homeostasis axis in MI/RI. By targeting MARCHF7-ATP7A interaction, HMC sustains copper export machinery to combat cuproptosis-driven injury. These findings position HMC as a novel therapeutic candidate for MI/RI through regulating ubiquitination-dependent regulation of copper homeostasis.</p>\",\"PeriodicalId\":9262,\"journal\":{\"name\":\"British Journal of Pharmacology\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":7.7000,\"publicationDate\":\"2025-08-14\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"British Journal of Pharmacology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1111/bph.70171\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"British Journal of Pharmacology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/bph.70171","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

摘要

背景与目的:心肌缺血再灌注损伤(MI/RI)是心肌梗死患者血运重建术后预后不良的主要原因,但靶向治疗仍是一个难以捉摸的问题。虽然橙皮苷甲基查尔酮(HMC)显示出抗氧化和血管保护特性,但其在MI/RI期间调节受调节的细胞死亡途径中的作用尚不清楚。本研究探讨了HMC对心肌梗死/心肌梗死的心脏保护作用及其潜在机制。实验方法:采用H9c2心肌细胞缺氧/再氧合(H/R)模型和小鼠MI/RI模型。研究了HMC对心肌功能、铜通量分析、泛素化分析和分子对接、线粒体完整性和心肌梗死/心肌梗死后细胞死亡模式的影响。关键结果:HMC预处理对MI/RI小鼠具有显著的心脏保护作用,可减少梗死面积,改善心功能。在机制上,HMC特异性地减弱了铜还原,这可以通过铜过载的减少和铜还原效应的下调来证明,这模仿了铜螯合剂四硫钼酸铵(ATTM)的作用。至关重要的是,铜增生诱导剂埃雷斯克洛莫尔-铜(Es-Cu)消除了HMC的心脏保护作用。此外,HMC与E3泛素连接酶MARCHF7相互作用,破坏MARCHF7/ATP7A复合物,从而减少铜输出物ATP7A的泛素化和蛋白酶体降解。ATP7A的稳定增强了铜外排,减轻了心肌梗死/心肌梗死引起的铜退化、氧化应激、炎症和线粒体损伤。结论和意义:我们的工作揭示了一个泛素调节的铜稳态轴在MI/RI。通过靶向MARCHF7-ATP7A相互作用,HMC维持铜出口机制以对抗铜中毒引起的损伤。这些发现表明,HMC通过调节泛素化依赖的铜稳态调节,成为MI/RI的一种新的治疗候选药物。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
HMC ameliorates myocardial ischaemia-reperfusion injury through suppressing cuproptosis via the de-ubiquitination and stabilization of ATP7A.

Background and purpose: Myocardial ischaemia-reperfusion injury (MI/RI) is a major contributor to poor prognosis following revascularization in myocardial infarction patients, yet targeted therapies remain elusive. While hesperidin methyl chalcone (HMC) demonstrates antioxidant and vasoprotective properties, its role in modulating regulated cell death pathways during MI/RI is undefined. This study investigates the cardioprotective effects of HMC against MI/RI and its underlying mechanisms.

Experimental approach: Hypoxia/reoxygenation (H/R) models in H9c2 cardiomyocytes and a model of MI/RI in mice were employed. The effects of HMC on cardiac performance, copper flux analysis, ubiquitination assays and molecular docking, mitochondrial integrity and cell death modalities in response to MI/RI were examined.

Key results: HMC pretreatment exhibited significant cardioprotection, reducing infarct size and improving cardiac function in MI/RI mice. Mechanistically, HMC specifically attenuated cuproptosis, as evidenced by decreased copper overload and downregulation of cuproptosis effectors, mimicking the action of the copper chelator ammonium tetrathiomolybdate (ATTM). Crucially, the cuproptosis inducer elesclomol-Cu (Es-Cu) abolished the cardioprotective effects of HMC. Furthermore, HMC interacted with the E3 ubiquitin ligase MARCHF7, and disrupted the complex of MARCHF7/ATP7A, thereby reducing ubiquitination and proteasomal degradation of the copper exporter ATP7A. The stabilization of ATP7A enhanced copper efflux, alleviating cuproptosis, oxidative stress, inflammation and mitochondrial damage induced by MI/RI.

Conclusions and implications: Our work unveils a ubiquitin-regulated copper homeostasis axis in MI/RI. By targeting MARCHF7-ATP7A interaction, HMC sustains copper export machinery to combat cuproptosis-driven injury. These findings position HMC as a novel therapeutic candidate for MI/RI through regulating ubiquitination-dependent regulation of copper homeostasis.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
15.40
自引率
12.30%
发文量
270
审稿时长
2.0 months
期刊介绍: The British Journal of Pharmacology (BJP) is a biomedical science journal offering comprehensive international coverage of experimental and translational pharmacology. It publishes original research, authoritative reviews, mini reviews, systematic reviews, meta-analyses, databases, letters to the Editor, and commentaries. Review articles, databases, systematic reviews, and meta-analyses are typically commissioned, but unsolicited contributions are also considered, either as standalone papers or part of themed issues. In addition to basic science research, BJP features translational pharmacology research, including proof-of-concept and early mechanistic studies in humans. While it generally does not publish first-in-man phase I studies or phase IIb, III, or IV studies, exceptions may be made under certain circumstances, particularly if results are combined with preclinical studies.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信